Optimi Health Adds Melanie Pump to Its Board

Melanie Pump has more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies.

Rhea-AI Filing Summary

Optimi Health Corp. (OPTH) appointed Melanie Pump to its Board of Directors on September 29, 2026. Pump is Chief Financial Officer of Qu Data Centres and has more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She also serves on the board of Mobio Technologies Inc. and previously served as a director of BTCS Inc.

Leah Hodges resigned as Corporate Secretary, and Chief Executive Officer Dane Stevens was appointed to fill the role.

Key Figures

Professional experience: More than 25 years

1 metrics

Professional experience More than 25 years Ms. Pump's experience across technology, digital infrastructure, software, fintech and emerging growth companies

Key Terms

GMP-grade, active pharmaceutical ingredients, Authorized Prescriber Scheme, Special Access Program

4 terms

GMP-grade technical

"manufacturing and distributing GMP-grade psychedelic drug products"

GMP-grade means a drug substance, ingredient or product was manufactured under Good Manufacturing Practice standards — a set of rules and documented controls that ensure consistent cleanliness, quality and traceability. For investors, GMP-grade items matter because they lower regulatory and safety risk, make products eligible for approval and sale in regulated markets, and reduce the chance of costly recalls or supply disruptions; think of it like food prepared in a certified commercial kitchen rather than a home stove.

active pharmaceutical ingredients medical

"Optimi supplies both active pharmaceutical ingredients and finished dosage forms"

The active pharmaceutical ingredient (API) is the specific chemical or biological substance in a medicine that produces the intended health effect — the ‘engine’ that treats, prevents or diagnoses a condition. Investors watch APIs because they determine a drug’s cost, quality, regulatory approval and patent protection; shortages, manufacturing problems or competition at the API level can directly affect a drug maker’s sales and valuation.

Authorized Prescriber Scheme regulatory

"currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme"

An authorized prescriber scheme lets a qualified clinician or group of clinicians prescribe a specific medicine to eligible patients without obtaining individual approvals each time, under rules set by health regulators. For investors, it matters because the scheme can speed access to medicines and broaden sales once clinicians are approved, similar to giving a trusted shopkeeper a standing license to sell a product rather than requiring a new permit for every sale.

Special Access Program regulatory

"accessible in Canada through the Special Access Program"

A special access program is a regulated pathway that lets patients use an experimental drug, vaccine, or medical device outside clinical trials when no approved options are available. Think of it like allowing a small number of people to try a prototype product before wide release; for investors it can create early, limited revenue, generate real‑world safety and use data, and carry regulatory and reputational risks that can affect a company’s valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who joined the OPTH board?

Melanie Pump was appointed to Optimi Health Corp.’s Board of Directors. She is Chief Financial Officer of Qu Data Centres and also serves on the board of Mobio Technologies Inc.

Who replaced Leah Hodges as OPTH's corporate secretary?

Chief Executive Officer Dane Stevens was appointed to fill the Corporate Secretary role after Leah Hodges resigned.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 07:30 AM Accepted by SEC EDGAR 09/29/2026 - 07:30 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-43304

Optimi Health Corp.
(Translation of registrant's name into English)

269 David Brown Way
Princeton, B.C. V0X 1W0
Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Press Release and Material Change Report

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Optimi Health Corp.
		(Registrant)
Date: September 29, 2026		/s/ Dane Stevens
		Dane Stevens
		Chief Executive Officer, Chief Marketing Officer and Director

EXHIBIT 99.1

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1	Name and Address of Company
	Optimi Health Corp. (the “Company”) 269 David Brown Way Po Box 728 Princeton, BC V0X 1W0
Item 2	Date of Material Changes
	September 29, 2026.
Item 3	News Releases
	A news release with respect to the material change was disseminated by the Company on September 29, 2026, through GlobeNewswire and filed on SEDAR+.
Item 4	Summary of Material Change
	On September 29, 2026, the Company announced the appointment of Melanie Pump to its Board of Directors (the "Board").
Item 5	Full Description of Material Changes: On September 29, 2026, the Company announced the appointment of Melanie Pump to the Board. The Company also announced that Leah Hodges had resigned as Corporate Secretary of the Company. Dane Stevens, the Company’s Chief Executive Officer has been appointed to fill the role.
Item 6	Reliance on Section 7.1(2) of National Instrument 51-102
	Not applicable.
Item 7	Omitted Information
	Not applicable.
Item 8	Executive Officer The name and business telephone number of the officer of the Company who can answer questions regarding this material change report is as follows:
	Dane Stevens, Chief Executive Officer dane@optimihealth.ca 778-899-4367
Item 9	Date of Report
	September 29, 2026

 

Optimi Health Appoints Melanie Pump to Board of Directors

Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the “Company"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "Board").

Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.

"We are pleased to welcome Melanie to Optimi’s Board," said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. "Her extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company board experience, will add valuable perspective as Optimi continues to execute on its strategic priorities and advance its position in the regulated psychedelic pharmaceutical market."

Ms. Pump also currently serves on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO) and previously served as a director of BTCS Inc. Her background combines senior financial leadership with public company governance experience across a range of technology-focused and growth-oriented businesses.

“I’m pleased to join Optimi’s Board at an important stage in the Company’s development,” said Melanie Pump. “Optimi has built a strong foundation in regulated psychedelic drug manufacturing and is advancing meaningful opportunities for growth. I look forward to working with Dane, the Board and the broader leadership team, and to contributing my experience in finance, governance and emerging growth companies as Optimi continues to execute on its strategic priorities.”

The Company also announces that Leah Hodges has resigned as Corporate Secretary of the Company. Dane Stevens, the Company’s Chief Executive Officer has been appointed to fill the role. The Company thanks Mrs. Hodges for her service.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Future results may differ materially from those expressed or implied in any forward-looking statement. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. In this news release, forward-looking statements and forward-looking information relate to, among other things, information regarding: the Company’s execution of its strategic priorities, position in the regulated psychedelic pharmaceutical market, opportunities for growth, and the contribution of Ms. Pump's experience going forward. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These risk factors include, among other things, market acceptance of the Company’s products, as well as those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.com and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 14.2 KB